Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Exp Psychol Appl ; 28(3): 606-628, 2022 Sep.
Article in English | MEDLINE | ID: mdl-34723571

ABSTRACT

Spatial and temporal factors are known to highly influence tactile perception, but their role has been largely unexplored in the case of two-dimensional (2D) pattern recognition. We investigated whether recognition is facilitated by the spatial and/or temporal separation of pattern elements, or by conditions known to favor perceptual integration, such as the ones eliciting apparent movement. 2D vibrotactile patterns were presented to the abdomen of novice participants. In Experiment 1, we manipulated the spatial (inter-tactor distance) and temporal (burst duration and inter-burst interval) parameters applied to the tracing mode (sequential activation of pattern elements). In Experiment 2, we compared display modes differing in their level of temporal overlap in the presentation of pattern elements: the static mode (simultaneous activation of pattern elements), the slit-scan mode (pattern revealed line by line), and the tracing mode. The results of both experiments reveal that (a) recognition performance increases with the isolation of pattern elements in space and/or in time, (b) spatial and temporal factors interact in pattern recognition, and (c) conditions leading to apparent movement tend to be associated with lower recognition accuracy. These results further our understanding of tactile perception and provide guidance for the design of future vibrotactile communication systems. (PsycInfo Database Record (c) 2022 APA, all rights reserved).


Subject(s)
Touch Perception , Vibration , Abdomen , Humans , Movement , Recognition, Psychology , Touch/physiology , Touch Perception/physiology
2.
Comput Help People Spec Needs ; 12376: 475-484, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33225323

ABSTRACT

Augmented reality (AR) has great potential for blind users because it enables a range of applications that provide audio information about specific locations or directions in the user's environment. For instance, the CamIO ("Camera Input-Output") AR app makes physical objects (such as documents, maps, devices and 3D models) accessible to blind and visually impaired persons by providing real-time audio feedback in response to the location on an object that the user is touching (using an inexpensive stylus). An important feature needed by blind users of AR apps such as CamIO is a 3D spatial guidance feature that provides real-time audio feedback to help the user find a desired location on an object. We have devised a simple audio interface to provide verbal guidance towards a target of interest in 3D. The experiment we report with blind participants using this guidance interface demonstrates the feasibility of the approach and its benefit for helping users find locations of interest.

3.
Lancet ; 377(9769): 905-13, 2011 Mar 12.
Article in English | MEDLINE | ID: mdl-21345487

ABSTRACT

BACKGROUND: Helicobacter pylori is associated with benign and malignant diseases of the upper gastrointestinal tract, and increasing antibiotic resistance has made alternative treatments necessary. Our aim was to assess the efficacy and safety of a new, single-capsule treatment versus the gold standard for H pylori eradication. METHODS: We did a randomised, open-label, non-inferiority, phase 3 trial in 39 sites in Europe, comparing the efficacy and safety of 10 days of quadruple therapy with omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline (quadruple therapy) versus 7 days of omeprazole, amoxicillin, and clarithromycin (standard therapy) in adults with recorded H pylori infection. Patients were randomly assigned treatment according to a predetermined list independently generated by Quintiles Canada (Ville St-Laurent, QC, Canada). Our study was designed as a non-inferiority trial but was powered to detect superiority. Our primary outcome was H pylori eradication, established by two negative (13)C urea breath tests at a minimum of 28 and 56 days after the end of treatment. Our assessment for non-inferiority was in the per-protocol population, with subsequent assessment for superiority in the intention-to-treat population (ie, all participants randomly assigned treatment). This study is registered with ClinicalTrials.gov, number NCT00669955. FINDINGS: 12 participants were lost to follow-up and 101 were excluded from the per-protocol analysis. In the per-protocol population (n=339), the lower bound of the CI for treatment with quadruple therapy was greater than the pre-established non-inferiority margin of -10% (95% CI 15·1-32·3; p<0·0001). In the intention-to-treat population (n=440), eradication rates were 80% (174 of 218 participants) in the quadruple therapy group versus 55% (123 of 222) in the standard therapy group (p<0·0001). Safety profiles for both treatments were similar; main adverse events were gastrointestinal and CNS disorders. INTERPRETATION: Quadruple therapy should be considered for first-line treatment in view of the rising prevalence of clarithromycin-resistant H pylori, especially since quadruple therapy provides superior eradication with similar safety and tolerability to standard therapy. FUNDING: Axcan Pharma Inc.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Ulcer Agents/administration & dosage , Helicobacter Infections/drug therapy , Helicobacter pylori , Adolescent , Adult , Amoxicillin/administration & dosage , Anti-Ulcer Agents/adverse effects , Breath Tests , Clarithromycin/administration & dosage , Clarithromycin/adverse effects , Drug Combinations , Drug Resistance, Bacterial , Drug Therapy, Combination , Female , Helicobacter Infections/diagnosis , Humans , Male , Metronidazole/administration & dosage , Metronidazole/adverse effects , Middle Aged , Omeprazole/administration & dosage , Omeprazole/adverse effects , Organometallic Compounds/administration & dosage , Organometallic Compounds/adverse effects , Tablets , Tetracycline/administration & dosage , Tetracycline/adverse effects , Young Adult
4.
J Hepatol ; 54(5): 1011-9, 2011 May.
Article in English | MEDLINE | ID: mdl-21145828

ABSTRACT

BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with increased morbidity and mortality. Ursodeoxycholic acid (UDCA) may have antioxidant, anti-inflammatory, and antifibrotic properties and may reduce liver injury in NASH. To date, no studies have assessed the efficacy and safety of high-dose UDCA (HD-UDCA) in patients with NASH. METHODS: We conducted a 12-month, randomized, double-blind, placebo-controlled multicenter trial to evaluate the efficacy and safety of HD-UDCA (28-35 mg/kg per day) in 126 patients with biopsy-proven NASH and elevated alanine aminotransferase (ALT) levels. The primary study end point was reduction in ALT levels from baseline in patients treated with HD-UDCA compared with placebo. Secondary study end points were the proportion of patients with ALT normalization, relative reduction in the scores of serum markers of fibrosis and hepatic inflammation, and safety and tolerability. RESULTS: HD-UDCA significantly reduced mean ALT levels -28.3% from baseline after 12 months compared with -1.6% with placebo (p<0.001). At the end of the trial, ALT levels normalized (≤35 IU/L) in 24.5% of patients treated with HD-UDCA and in 4.8% of patients who received placebo (p=0.003). Both results were not accounted for by changes in weight during the trial. HD-UDCA significantly reduced the FibroTest® serum fibrosis marker (p<0.001) compared with placebo. HD-UDCA also significantly improved markers of glycemic control and insulin resistance. There were no safety issues in this population. CONCLUSIONS: Treatment with HD-UDCA was safe, improved aminotransferase levels, serum fibrosis markers, and selected metabolic parameters. Studies with histologic end points are warranted.


Subject(s)
Cholagogues and Choleretics/administration & dosage , Ursodeoxycholic Acid/administration & dosage , Adult , Blood Glucose/drug effects , Cholagogues and Choleretics/adverse effects , Dose-Response Relationship, Drug , Fatty Liver/drug therapy , Fatty Liver/metabolism , Female , Follow-Up Studies , Glycated Hemoglobin/metabolism , Humans , Insulin/blood , Insulin Resistance , Male , Middle Aged , Non-alcoholic Fatty Liver Disease , Treatment Outcome , Ursodeoxycholic Acid/adverse effects
5.
Antimicrob Agents Chemother ; 53(7): 3081-7, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19414580

ABSTRACT

Shiga toxin (Stx)-producing Escherichia coli (STEC) causes hemorrhagic colitis and hemolytic-uremic syndrome (HUS). The rates of STEC infection and complications, including death, are highest among young children and elderly individuals. There are no causal therapies. Because Stx is the primary pathological agent leading to organ injury in patients with STEC disease, therapeutic antibodies are being developed to neutralize systemically absorbed toxin during the early phase of the infection. Two phase I, single-dose, open-label, nonrandomized studies were conducted to evaluate the safety and pharmacokinetics of the chimeric monoclonal antibodies (antitoxins) against Stx 1 and 2 (calphaStx1 and calphaStx2, respectively). In the first study, 16 volunteers received 1 or 3 mg/kg of body weight of calphaStx1 or calphaStx2 as a single, short (1-h) intravenous infusion (n = 4 per group). In a second study, 10 volunteers received a 1-h infusion of calphaStx1 and calphaStx2 combined at 1 or 3 mg/kg (n = 5 per group). Treatment-emergent adverse events were mild, resolved spontaneously, and were generally unrelated to the antibody infusion. No serious adverse events were observed. Human antichimeric antibodies were detected in a single blood sample collected on day 57. Antibody clearance was slightly greater for calphaStx1 (0.38 +/- 0.16 ml/h/kg [mean +/- standard deviation]) than for calphaStx2 (0.20 +/- 0.07 ml/h/kg) (P = 0.0013, t test). The low clearance is consistent with the long elimination half-lives of calphaStx1 (190.4 +/- 140.2 h) and calphaStx2 (260.6 +/- 112.4 h; P = 0.151). The small volume of distribution (0.08 +/- 0.05 liter/kg, combined data) indicates that the antibodies are retained within the circulation. The conclusion is that calphaStx1 and calphaStx2, given as individual or combined short intravenous infusions, are well tolerated. These results form the basis for future safety and efficacy trials with patients with STEC infections to ameliorate or prevent HUS and other complications.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/pharmacokinetics , Shiga Toxin 1/metabolism , Shiga Toxin 2/metabolism , Adult , Female , Humans , Male , Middle Aged , Young Adult
6.
Int J Radiat Oncol Biol Phys ; 64(3): 935-40, 2006 Mar 01.
Article in English | MEDLINE | ID: mdl-16376493

ABSTRACT

PURPOSE: To assess the impact of bladder instillations of hyaluronic acid (HA) on the prevalence of urinary tract infection (UTI) in patients receiving emergency radiotherapy for metastatic spinal cord compression. METHODS AND MATERIALS: Patients were recruited consecutively at one center and assigned to usual care (UC) (n = 34, mean age 62.2 years) or UC with once-weekly HA instillation (UC + HA) (Cystistat: 40 mg in 50 mL phosphate-buffered saline) (n = 37; mean age, 63.1 years). All patients had an indwelling catheter and received radiotherapy. UTI status was assessed at baseline and during hospitalization. RESULTS: At baseline, patient groups were comparable, except for the prevalence of UTI at baseline, which was 11.8% and 0% in the UC and UC + HA patients, respectively (p = 0.0477). During hospitalization, 76.5% (vs. 11.8% at baseline, p < 0.0001) of the UC patients had a UTI compared with 13.5% (vs. 0% at baseline, p = 0.0541) of the UC + HA patients (p < 0.0001). Both groups were hospitalized for similar periods (19.8 days [UC] vs. 18.5 days, p = 0.4769) and received equivalent radiotherapy sessions (4.6 [UC] vs. 5.8 sessions, p = 0.2368). CONCLUSIONS: Patients receiving UC + HA had a 5.7-fold decrease in UTI prevalence over the hospitalization period compared to UC patients, suggesting that bladder instillations of HA effectively prevent UTI in patients with indwelling catheters receiving radiotherapy for nerve compression.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Hyaluronic Acid/administration & dosage , Spinal Cord Compression/radiotherapy , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Urinary Tract Infections/prevention & control , Administration, Intravesical , Adult , Aged , Aged, 80 and over , Catheters, Indwelling/adverse effects , Female , Humans , Male , Middle Aged , Pilot Projects , Prevalence , Urinary Catheterization/adverse effects , Urinary Tract Infections/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...